What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
Walter Reinisch focuses on Internal medicine, Gastroenterology, Surgery, Ulcerative colitis and Inflammatory bowel disease.
His research in Internal medicine tackles topics such as Placebo which are related to areas like Clinical endpoint.
His Gastroenterology study integrates concerns from other disciplines, such as Area under the curve, Azathioprine, Fecal bacteriotherapy and Mesalazine.
His work deals with themes such as Crohn's Disease Activity Index, Adalimumab, Clinical trial and C-reactive protein, which intersect with Surgery.
The Ulcerative colitis study combines topics in areas such as Maintenance therapy, Colitis and Diarrhea.
His Inflammatory bowel disease research incorporates elements of Physical therapy, Immunology, Prospective cohort study and Intensive care medicine.
His most cited work include:
- Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2790 citations)
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease (2157 citations)
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (1018 citations)
What are the main themes of his work throughout his whole career to date?
Walter Reinisch mainly focuses on Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease.
His research combines Surgery and Internal medicine.
His research in Gastroenterology focuses on subjects like Placebo, which are connected to Clinical endpoint.
His studies in Crohn's disease integrate themes in fields like Post-hoc analysis, Randomized controlled trial and Immunology.
He has researched Ulcerative colitis in several fields, including Tofacitinib, Colitis, Clinical trial, Adverse effect and Golimumab.
His study in Inflammatory bowel disease is interdisciplinary in nature, drawing from both Prospective cohort study and Intensive care medicine.
He most often published in these fields:
- Internal medicine (73.78%)
- Gastroenterology (48.40%)
- Crohn's disease (42.26%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (73.78%)
- Ulcerative colitis (38.08%)
- Crohn's disease (42.26%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Ulcerative colitis, Crohn's disease, Gastroenterology and Inflammatory bowel disease.
Internal medicine and Placebo are frequently intertwined in his study.
The study incorporates disciplines such as Tofacitinib, Open label, Extension study, Addressin and Antibody in addition to Ulcerative colitis.
The various areas that Walter Reinisch examines in his Crohn's disease study include Post-hoc analysis, Adalimumab and Intensive care medicine.
In his research on the topic of Gastroenterology, Feces is strongly related with Calprotectin.
His Inflammatory bowel disease research is multidisciplinary, incorporating elements of Logistic regression, Clinical trial, Arthritis, Golimumab and Quality of life.
Between 2017 and 2021, his most popular works were:
- Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. (211 citations)
- Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. (94 citations)
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis (64 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Surgery
Internal medicine, Crohn's disease, Ulcerative colitis, Gastroenterology and Inflammatory bowel disease are his primary areas of study.
In his research, Clinical endpoint is intimately related to Placebo, which falls under the overarching field of Internal medicine.
The concepts of his Crohn's disease study are interwoven with issues in Adalimumab, Immunology and C-reactive protein.
His Ulcerative colitis study incorporates themes from Patient-reported outcome, Tofacitinib, Colitis, Incidence and Cancer research.
His Stool frequency study in the realm of Gastroenterology connects with subjects such as Neoadjuvant therapy.
His Inflammatory bowel disease research integrates issues from Multiple sclerosis, Golimumab, Clinical trial and Arthritis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
